Glaucoma Newswire

Glaucoma Newswire

Comprehensive Real-Time News Feed for Glaucoma.

Results 1 - 20 of 658 in Glaucoma

  1. New research adds evidence on potential treatments targeting amyloid beta in Alzheimer'sRead the original story w/Photo

    19 hrs ago | EurekAlert!

    ... CAI medications -- previously approved by the U.S. Food and Drug Administration (FDA) for other conditions like glaucoma -- target the mechanism behind this dysfunction. "Therapies aimed at preventing mitochondrial failure may represent promising ...

    Comment?

  2. Richard L. Harrison Sells 10,000 Shares of Glaukos Corp. (GKOS) StockRead the original story w/Photo

    15 hrs ago | AmericanBankingNews.com

    ... The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent, an MIGS device ...

    Comment?

  3. Stem Cell Therapy as a Potential Glaucoma TreatmentRead the original story w/Photo

    Yesterday | Fight Aging!

    ... here provide evidence in mice to suggest that stem cell treatments could be used to address some forms of glaucoma , usually caused by an increase in pressure in the eye that can damage the optic nerve and other structures. The types of glaucoma of ...

    Comment?

  4. Mice study shows stem cell infusion could help treat glaucomaRead the original story w/Photo

    Tuesday | Medical News

    An infusion of stem cells could help restore proper drainage for fluid-clogged eyes at risk for glaucoma. That's the upshot of a study led by a Veterans Affairs and University of Iowa team.

    Comment?

  5. BioLight Reports Successful Feasibility Clinical Study Results For...Read the original story

    Monday Jul 25 | BioSpace

    ... various commercial and clinical stages, including: IOPtiMatea , a laser-based non-invasive surgical treatment for glaucoma; TeaRxa , a diagnostic solution that provides a multi-assay analysis of tear film constituents in order to identify one or ...

    Comment?

  6. When States Legalize Medical Marijuana, People Use Fewer Prescription PainkillersRead the original story w/Photo

    Monday Jul 25 | ThinkProgress

    ... specifically at nine conditions for which marijuana can be used as an alternative treatment: anxiety, depression, glaucoma, nausea, pain, psychosis, seizures, sleep disorders, and spasticity. In the 17 states plus Washington, D.C. that had legalized ...

    Comment?

  7. Iguana Healthcare Management LLC Takes Position in Glaukos Corp.Read the original story w/Photo

    Monday Jul 25 | Daily Political

    ... The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent, an MIGS device ...

    Comment?

  8. Valeanta s New Glaucoma Drug Raises No Safety or Efficacy Concerns With FDARead the original story w/Photo

    Sunday Jul 24 | Vision Monday

    LAVAL, Quebec- Valeant Pharmaceuticals International announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration regarding the New Drug Application for latanoprostene bunod ophthalmic solution, 0.024 percent, an intraocular pressure lowering single-agent eye drop for patients with open angle glaucoma or ocular hypertension. The concerns raised by the FDA pertain to a Current Good Manufacturing Practice inspection at Bausch + Lomb's manufacturing facility in Tampa, Fla.

    Comment?

  9. Valeant stock slides after feds flunk new glaucoma drug :0Read the original story

    Friday Jul 22 | New York Post

    Ackman's Pershing Square has a 6 percent stake in the Canadian company. Just days ago, he and his team said they expected the Food and Drug Administration to approve the drug, called brodalumab.

    Comment?

  10. FDA Rejects Latanoprostene Eye Drops for GlaucomaRead the original story

    Friday Jul 22 | P&T Community

    Valeant Pharmaceuticals has received a complete response letter from the FDA regarding the company's new drug application for latanoprostene bunod ophthalmic solution 0.024%, an intraocular pressure-lowering single-agent eye drop for patients with open-angle glaucoma or ocular hypertension . The concerns raised by the FDA pertain to a current good manufacturing practice inspection at Bausch + Lomb's manufacturing facility in Tampa, Florida, where some deficiencies were identified.

    Comment?

  11. Valeant Hits Another BumpRead the original story w/Photo

    Friday Jul 22 | TheStreet.com

    One of a trio of potentially lucrative Valeant Pharmaceutical drugs that are currently under FDA review failed to pass regulatory muster after an FDA inspection of a manufacturing plant raised eyebrows. Bausch & Lomb, the eye care giant and Valeant subsidiary that billionaire activist Bill Ackman has called one of Valeant's "crown jewel" assets, is the manufacturer behind the product, labeled latanoprostene bunod, which is being tested as an eye drop to treat glaucoma and hypertension.

    Comment?

  12. Valeant (VRX) Stock Down on Concerns About Glaucoma TreatmentRead the original story w/Photo

    Friday Jul 22 | TheStreet.com

    Shares of Valeant Pharmaceuticals are declining 3.02% to $23.74 in early-morning trading on Friday after the FDA failed to approve a Bausch & Lomb glaucoma treatment. In a complete response letter about an eye drop for a type of glaucoma, the agency raised concerns about manufacturing issues at a Bausch & Lomb facility.

    Comment?

  13. Inotek Pharmaceuticals Corporation Expands Intellectual Property Portfolio With Combination PatentRead the original story

    Thursday Jul 21 | BioSpace

    Inotek Pharmaceuticals Corporation , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other eye diseases, today announced that the United States Patent and Trademark Office issued a composition of matter patent for the combination of the Company's lead product candidate, trabodenoson, with a prostaglandin analog for the treatment of intraocular pressure in patients with glaucoma. US Patent number 9,370,530 further strengthens the Company's patent estate for trabodenoson and adds composition of matter intellectual property protection for the combination or kit treatment option until 2031.

    Comment?

  14. Inotek Pharmaceuticals Expands Intellectual Property Portfolio with Combination PatentRead the original story w/Photo

    Friday Jul 22 | Freshnews

    Inotek Pharmaceuticals expands intellectual property portfolio with combination patent of trabodenoson with a prostaglandin analog for the treatment of intraocular pressure . Inotek Pharmaceuticals Corporation , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other eye diseases, today announced that the United States Patent and Trademark Office issued a composition of matter patent for the combination of the Company's lead product candidate, trabodenoson, with a prostaglandin analog for the treatment of intraocular pressure in patients with glaucoma.

    Comment?

  15. Valeant Drug Approval Hampered by FDA Facility InspectionRead the original story w/Photo

    Friday Jul 22 | TheStreet.com

    Bausch & Lomb, the eyecare giant and Valeant subsidiary that billionaire activist Bill Ackman has called one of Valeant's "crown jewel" assets, is the manufacturer behind the product, labeled latanoprostene bunod, which is being tested as an eye drop to treat glaucoma and hypertension. Valeant said in a Friday release that the FDA sent the debt-laden Canadian drugmaker a Complete Response Letter following the submission of Valeant's New Drug Application filing, citing concerns raised by an inspection of the Bausch & Lomb manufacturing plant in Tampa.

    Comment?

  16. Pitt's Innovation Institute helps create 13 startup companies this yearRead the original story w/Photo

    Friday Jul 22 | Post-gazette.com

    ... Facher said. Among the companies formed during the past year were Ocugenix, which licensed Pitt technology to treat glaucoma and macular degeneration; Interphase Materials, which has developed a technology for durable coatings; and SkinJet Inc., ...

    Comment?

  17. Pitt Innovation Institute Reports Record-High Results for Fiscal Year 2016Read the original story

    Thursday Jul 21 | PressReleasePoint

    ... several based in Pittsburgh, including Ocugenix which has an exclusive option to license Pitt technology to treat glaucoma and macular degeneration; Interphase Materials which has developed antifouling compounds licensed from Pitt for preventing the ...

    Comment?

  18. Ackman On Valeant And HerbalifeRead the original story w/Photo

    Thursday Jul 21 | Seeking Alpha

    ... be a $1B+ opportunity for Valeant, which is sizeable in the context of total revenue: Latanoprostene bunod is a glaucoma treatment. It is up for potential approval this month as well. Pershing highlighted how it did better in trial than the current ...

    Comment?

  19. Valeant's Drug Approvals May Save the DayRead the original story w/Photo

    Wednesday Jul 20 | TheStreet.com

    ... regimens and warning labels due to risks that Brodalumab may cause suicidal thinking among patients). Together with glaucoma treatment Latanoprostene bunod, which is under FDA review and slated for approval this month, Valeant could rake in as much ...

    Comment?

  20. Valeant (VRX) Stock Gains as FDA Approves Anticonstipation DrugRead the original story w/Photo

    Wednesday Jul 20 | TheStreet.com

    ... Brodalumab on the condition that the company enacts measures to mitigate suicide risk. In conjunction with glaucoma treatment Latanoprostene bunod, which is under FDA review and expected to be approved this month, Valeant could generate as much as ...

    Comment?